Loading...
XSHG
600201
Market cap2.00bUSD
Jul 10, Last price  
12.18CNY
1D
0.00%
1Q
-18.58%
Jan 2017
-29.84%
Name

Jinyu Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:600201 chart
P/E
135.26
P/S
9.70
EPS
0.09
Div Yield, %
0.25%
Shrs. gr., 5y
-0.79%
Rev. gr., 5y
-2.46%
Revenues
1.40b
+11.23%
561,866,923702,180,147815,014,679675,501,327670,330,720576,140,310556,475,105671,382,9781,062,932,0241,246,505,8441,517,019,2821,901,010,2631,896,608,6291,126,782,2521,581,905,6311,776,317,8111,528,669,2561,598,225,4601,255,455,7571,396,413,685
Net income
100m
-8.14%
38,244,00092,925,47172,207,19966,473,720115,188,976149,438,394130,434,793250,883,064404,321,362479,727,744644,541,675870,094,416754,465,557221,041,640406,195,468382,286,670210,659,929283,630,795108,985,190100,111,637
CFO
343m
+18.50%
102,662,785136,094,806223,910,89800185,203,233102,946,417649,339,640585,186,590494,320,157756,123,716891,439,596422,460,842405,242,914699,612,782533,084,549344,650,092414,833,263289,552,214343,117,706
Dividend
Jun 26, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Hohhot, China, Jinyu Bio-technology Co., Ltd. is a Chinese firm specializing in the development, production, and commercialization of biological products for animal health. Established in 1992, the company provides crucial vaccines designed to combat diseases such as foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever. These vital immunizations are supplied for a broad spectrum of animals, including pigs, poultry, ruminants, and companion pets. The entity formally adopted its current name, Jinyu Bio-technology Co., Ltd., in December 2015, having previously operated as Inner Mongolia Jinyu Group Co., Ltd.
IPO date
Jan 15, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT